JGHG yields 72.46% · ABBV yields 3.06%● Live data
📍 JGHG pulled ahead of the other in Year 1
Combined, JGHG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JGHG + ABBV for your $10,000?
Jinzisheng Holding Group, a development stage company, develops and sells enterprise mobile marketing applications solutions, kiosk hardware, and software products. Its solutions include m2Meet, a community networking software solution; m2Bank, a financial transactions system that facilitates bill payments, money transfers, and account management; and m2Market, a mobile marketing solution that is used to deliver marketing materials to mobile phones. The company also offers m2Ticket, a mobile ticketing sales engine, which manages the sale and delivery of tickets through mobile phones for the transportation and entertainment industry; m2Kiosk, a line of standard and custom kiosks hardware and software that integrates with mobile phone applications in the marketing, financial, and ticketing industries; and m2Workflow, a customer relations management solution on mobile phones for service industries. In addition, it develops and licenses portal software products that enable customers to operate their own online social networking portal without requiring any technical programming or Website design skills, as well as provides custom software programming services to customers who license its products. Further, the company specializes in data and voice telecommunications technologies. Jinzisheng Holding Group was founded in 2004 and is based in Toronto, Canada.
Full JGHG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.